The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Self-citationHistone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity
Pasini, D., Bracken, A. P., Jensen, M. R., Denchi, E. L., & Helin, K. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600402 · Cited by 916
Self-citationTumour predisposition in mice heterozygous for a targeted mutation in Nf1
Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., & Weinberg, R. A. (1994) · Nature Genetics · doi:10.1038/ng0794-353 · Cited by 778
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Self-citationPolycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
Sauvageau, M., & Sauvageau, G. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.002 · Cited by 586
Mouse Models of Tumor Development in Neurofibromatosis Type 1
Cichowski, K., Shih, T. S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., & Jacks, T. (1999) · Science · doi:10.1126/science.286.5447.2172 · Cited by 467
Self-citationPasini, D., Malatesta, M., Jung, H. R., Walfridsson, J., Willer, A., Olsson, L., Skotte, J., Wutz, A., Porse, B., Jensen, O. N., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq244 · Cited by 401
Self-citationMin, J., Zaslavsky, A., Fedele, G., McLaughlin, S. K., Reczek, E. E., De Raedt, T., Guney, I., Strochlic, D. E., MacConaill, L. E., Beroukhim, R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2100 · Cited by 380
Self-citationMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D., Widemann, B., Kim, M.-O., Dombi, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 334
Elevated Risk for MPNST in NF1 Microdeletion Patients
De Raedt, T., Brems, H., Wolkenstein, P., Vidaud, D., Pilotti, S., Perrone, F., Mautner, V., Frahm, S., Sciot, R., & Legius, E. (2003) · The American Journal of Human Genetics · doi:10.1086/374821 · Cited by 310
Self-citationStage-specific sensitivity to p53 restoration during lung cancer progression
Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A., Sanchez-Rivera, F. J., Resnick, R., Bronson, R., Hemann, M. T., et al. (2010) · Nature · doi:10.1038/nature09535 · Cited by 273
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.014 · Cited by 258
Self-citationAtypical neurofibromas in neurofibromatosis type 1 are premalignant tumors
Beert, E., Brems, H., Daniëls, B., De Wever, I., Van Calenbergh, F., Schoenaers, J., Debiec‐Rychter, M., Gevaert, O., De Raedt, T., Van Den Bruel, A., et al. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20921 · Cited by 255
Self-citationSelective activation of p53-mediated tumour suppression in high-grade tumours
Junttila, M. R., Karnezis, A. N., Garcia, D., Madriles, F., Kortlever, R. M., Rostker, F., Brown Swigart, L., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 245
TORC1 Is Essential for NF1-Associated Malignancies
Johannessen, C. M., Johnson, B. W., Williams, S. M. G., Chan, A. W., Reczek, E. E., Lynch, R. C., Rioth, M. J., McClatchey, A., Ryeom, S., & Cichowski, K. (2008) · Current Biology · doi:10.1016/j.cub.2007.11.066 · Cited by 203
Self-citationTP53 mutations are frequent in malignant NFI tumors
Legius, E., Dierick, H., Wu, R., Hall, B. K., Marynen, P., Cassiman, J., & Glover, T. W. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870100405 · Cited by 195
Self-citationRecombination hotspot in NF1 microdeletion patients
Lopez-Correa, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.13.1387 · Cited by 177
Mautner, V.-F., Kluwe, L., Friedrich, R. E., Roehl, A. C., Bammert, S., Högel, J., Spöri, H., Cooper, D. N., & Kehrer-Sawatzki, H. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2009.075937 · Cited by 173
Self-citationProteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis
McGillicuddy, L. T., Longo, J. F., Hollstein, P. E., Kubek, S., Beroukhim, R., Raedt, T. D., Johnson, B. W., Williams, S. M. G., Nghiemphu, P. L., Liau, L. M., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.009 · Cited by 170
Self-citationAn expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer
Maertens, O., & Cichowski, K. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.04.002 · Cited by 167
Self-citationThe RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
McLaughlin, S. K., Olsen, S. N., Dake, B. T., Raedt, T. D., Lim, E., Bronson, R. T., Beroukhim, R., Polyák, K., Brown, M. A., Kuperwasser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.004 · Cited by 147
Self-citationSprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
Shaw, A. T., Meissner, A., Dowdle, J. A., Crowley, D., Magendantz, M., Ouyang, C., Parisi, T., Rajagopal, J., Blank, L. J., Bronson, R. T., et al. (2007) · Genes & Development · doi:10.1101/gad.1526207 · Cited by 131
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice
Chang, T. Y., Krisman, K., Theobald, E. H., Xu, J., Akutagawa, J., Lauchle, J., Kogan, S. C., Braun, B. S., & Shannon, K. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63193 · Cited by 130
Xu, J., Haigis, K. M., Firestone, A. J., McNerney, M. E., Li, Q., Davis, E., Chen, S.-C., Nakitandwe, J., Downing, J. R., Jacks, T., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0096 · Cited by 71
Cited by
Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.4 · Cited by 862
Epigenetic balance of gene expression by Polycomb and COMPASS families
Piunti, A., & Shilatifard, A. (2016) · Science · doi:10.1126/science.aad9780 · Cited by 524
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.-S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. (2015) · Nature · doi:10.1038/nature14898 · Cited by 499
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
Miettinen, M. M., Antonescu, C. R., Fletcher, C. D. M., Kim, A., Lazar, A. J., Quezado, M. M., Reilly, K. M., Stemmer-Rachamimov, A., Stewart, D. R., Viskochil, D., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.010 · Cited by 439
Metadata
- Authors
- De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin, K., Hornick, J. L., Mautner, V., Kehrer-Sawatzki, H., Clapp, W., Bradner, J., Vidaud, M., Upadhyaya, M., Legius, E., & Cichowski, K.
- Venue
- Nature
- Published
- 2014-08-13
- Volume
- 514
- Issue
- 7521
- Pages
- 247-251
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2035208208
- Cited by
- 461
- References
- 31
- FWCI
- 17.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.